Ki-67 is a protein found in cells that are actively dividing, and pathologists measure it to gauge how fast a tumor is growing. The result, called the Ki-67 index, is the percentage of tumor cells that test positive for it. A higher index generally means a more aggressive, faster-growing cancer.
Origin
Ki-67 was discovered in the early 1980s by researchers in Kiel, Germany; the "Ki" stands for Kiel and "67" was the number of the original antibody clone. It has since become a standard marker of cell proliferation in cancer pathology.
Significance in Asbestos Context
In mesothelioma and asbestos-related lung cancer, a Ki-67 index helps doctors judge how aggressive the tumor is and can inform prognosis and treatment decisions. A high proliferation index may support a more aggressive treatment approach and can factor into estimates of survival. Because it appears in the pathology report, the Ki-67 value can also be part of the medical record used to describe disease severity in a claim. Patients can ask whether Ki-67 was measured and what their index means for their outlook.
Example Sentence
Her pathology report listed a Ki-67 index of 40 percent, which the oncologist said pointed to a more aggressive epithelioid mesothelioma.
Related Terms
Immunohistochemistry, Histological Grading, Proliferation Index, Prognosis, Epithelioid Mesothelioma, BAP1
Notes
- Ask your oncologist whether Ki-67 was tested and how your index compares with typical ranges for your tumor type.
- Ki-67 is one factor among several (cell type, stage, BAP1 status); don't read it in isolation.
- Keep the full pathology report; the Ki-67 index and other markers may matter for both treatment and documenting severity.
In the research library
64 studies in our medical research library mention Ki-67 in the title or abstract. Among the most cited:
- The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)S. Kusamura, P.A. Torres Mesa, A. Cabras, et al, 2016 · Annals of Surgical Oncology · cited 62 times
- Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue MicroarrayM. Deraco, A. Cabras, D. Baratti, et al, 2015 · Annals of Surgical Oncology · cited 22 times
- Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67F. Kimura, I. Okayasu, H. Kakinuma, et al, 2013 · Acta Cytologica · cited 15 times
- Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?F. Kimura, J. Kawamura, J. Watanabe, et al, 2010 · Diagnostic Cytopathology · cited 13 times
- Ki-67 Proliferation Index Is Associated With Tumor Grade and Survival in Pleural Epithelioid MesotheliomasB. Galeano, C.J. Smith, E.S. Yi, et al, 2024 · The American Journal of Surgical Pathology · cited 10 times
The journals that publish most on it: Pathology International (4), Cancers (4), Oncology Letters (3).
Category: Diagnostic Tools & Biomarkers · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.